Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
201. |
ECCT/24/06/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
202. |
ECCT/24/07/05 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Bernhards Ogutu Site(s) in Kenya 1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county) |
View |
203. |
ECCT/24/10/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county) |
View |
204. |
ECCT/24/03/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Prof Walter Godfrey Jaoko Site(s) in Kenya 1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
View |
205. |
ECCT/23/11/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD) |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. In this submission: International Cancer Institute (Uasin Gishu county) |
View |